Oncology Institute (DFPH) Receivables (2020 - 2026)

Oncology Institute has reported Receivables for 7 years, with the latest figure at $59.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 19.7% year-over-year to $59.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (up 19.7% YoY), and the FY2025 full-year result was $59.3 million, up 21.85% from the prior year.
• Receivables for Q1 2026 stood at $59.4 million, roughly flat from $59.3 million in the prior quarter.
• The five-year high for Receivables was $60.0 million in Q3 2025, with the low at $25.8 million in Q1 2022.
• Historically, Receivables has averaged $48.1 million across 5 years, with a median of $48.9 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables surged 90.33% — and 2025, when it retreated 16.0%.
• Oncology Institute's Receivables stood at $40.4 million in 2022, then gained by 6.13% to $42.9 million in 2023, then increased by 13.45% to $48.7 million in 2024, then grew by 21.85% to $59.3 million in 2025, then rose by 0.22% to $59.4 million in 2026.
• The last three Receivables figures came in at $59.4 million (Q1 2026), $59.3 million (Q4 2025), and $60.0 million (Q3 2025), per Business Quant data.